“It is simply imaginable that if cases increase rapidly in clinical trials, we can have this knowledge before regulators this year, and then there will be a procedure they will follow to make a full assessment of knowledge,” Andrew Pollard said. BBC Radio.
The Oxford vaccine showed wonderful promise in the first human trial when it produced an immune reaction and is one of the leading candidate vaccines.
The Oxford vaccine recently made headlines after the Financial Times reported that the Trump administration was contemplating accelerating the use of the vaccine in the United States ahead of the Nov. 3 election.
“The emergency use authorization procedure is well established, but it is still about conscientiously achieving knowledgeArray . . . and evidence that it works,” said the director of the Oxford Vaccine Group.
The complex clinical trial of the Oxford COVID-19 vaccine candidate in the country is expected to begin today through the Serum Institute of India (SII) in Pune.
The Serum Institute of India has partnered with The Anglo-Swedish pharmaceutical company AstraZeneca to manufacture the COVID-19 candidate vaccine, developed through the University of Oxford.
Earlier this month, the Comptroller-General for Medicines of India (DCGI) gave the Pune Serum Institute of India (SII) a go-ahead on 3 August for completing the Phase 2 and 3 human tests with the Oxford COVID-19 candidate vaccine in the country.
Testing should be carried out at 17 decided sites. Approximately another 1,600 people over the age of 18 are likely to participate in Oxford vaccine trials in India (with strong contributions).
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and informed
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.